Pfizer

News

Pfizer drops Beqvez, leaving its gene therapy cupboard bare

Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

News

BridgeBio gets EU nod for ATTR cardiomyopathy drug

BridgeBio and Bayer are poised to challenge Pfizer's Vyndaqel in the EU after acoramidis gets a green light for ATTR cardiomyopathy.

News

FDA clears new antibiotic for superbug infections

AbbVie has won FDA approval for Emblaveo, a new antibiotic to treat pathogens that pose serious public health threats.

News

GSK rides out vaccine sales weakness with cancer, HIV gains

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.

News

Pfizer builds on Braftovi bowel cancer OK with survival data

Pfizer's Braftovi - just approved by the FDA as a first-line treatment for colorectal cancer based on response data - also extends patient survival.

News

Pfizer offers $60m to settle prescriber kickback claims

Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT.

Pfizer drops Beqvez, leaving its gene therapy cupboard bare

BridgeBio gets EU nod for ATTR cardiomyopathy drug

FDA clears new antibiotic for superbug infections

GSK rides out vaccine sales weakness with cancer, HIV gains

Pfizer builds on Braftovi bowel cancer OK with survival data

Pfizer offers $60m to settle prescriber kickback claims

SanegeneBio raises $110m for RNAi, plus other financings

How to meet your physicians where they are online

Pfizer

Editor's Picks